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Abstract A speci¢c RNA aptamer (T705) against bovine
thrombin had been obtained after seven rounds of SELEX (sys-
tematic evolution of ligands by exponential enrichment) selec-
tion from a random RNA library previously. In order to further
investigate the relationship between the structure and function of
this aptamer, three truncated RNA aptamers, T705a, T705b
and T705c, were designed according to the secondary structure
of T705 RNA. Our results showed that T705c keeping the pre-
cise stem^loop structure but lacking most of the stem region
sequence of T705 could inhibit clot formation in vitro in the
same way as its parental form. We also report here that sin-
gle-stranded DNA (ssDNA) antisense oligonucleotides, cP and
cP-22, which were complementary to di¡erent portions of T705c
could act as e⁄cient antidotes reversing the inhibitory activity
of T705. It is demonstrated for the ¢rst time that ssDNA anti-
sense oligonucleotides are potential antidotes of RNA aptamers
and this may be an e¡ective, rapid strategy to ¢nd antidotes of
RNA aptamers which would be of important usefulness in basic
research and drug screening.
2 2004 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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1. Introduction
Bovine thrombin is widely used in clinical wound healing
after surgery. There is 85% homology between bovine throm-
bin and human thrombin, so most antibodies against bovine
thrombin cross-react with human thrombin. Rare antibodies
against bovine thrombin that do not cross-react with human
thrombin have been reported. The SELEX (systemic evolution
of ligands by exponential enrichment) combinatorial chemis-
try methodology has been extensively used in screening for
high-a⁄nity and speci¢c aptamers binding to the targets
[1^4]. We performed in vitro selection techniques to screen a
nucleic acid-based combinatorial library of about 1014 species
for RNA aptamers capable of binding and inhibiting bovine
thrombin-catalyzed ¢brin clot formation [5]. Two aptamers
that could bind bovine thrombin speci¢cally and did not
cross-react with human thrombin were obtained. Secondary
structure prediction revealed that one of the aptamers, T705
binding bovine thrombin with higher a⁄nity (dissociation
constant Kd = 168 nM), had potential stem^loop secondary
structure. In this report, we investigated the relationship be-
tween the secondary structure of aptamer T705 and its bio-
logical activity in vitro with di¡erent truncated T705 RNA
aptamers, and also found for the ¢rst time that single-
stranded DNA (ssDNA) antisense oligonucleotides could be
potential antidotes of RNA aptamers.
2. Materials and methods
2.1. Generation of truncated RNA aptamers
Three truncated RNA aptamers derived from aptamer T705 were
generated by in vitro transcription. Brie£y, ssDNA templates were
¢rst synthesized and then ampli¢ed by polymerase chain reaction
(PCR) with the following sequences:
T705a: 5P-TAATACGACTCACTATAGCAATGGTACGGTAC-
TTCCTTTGGAAGATAACCAAAAGTGCACGCTACTTTGCTA-
A-3P ; T705b: 5P-TAATACGACTCACTATAGCAATGGTACGG-
TACTTCCAAAAGCTGGAGAACTTTTCAAAAGTGCACGCTA-
CTTTGCTAA-3P ; T705c: 5P-TAATACGACTCACTATATTTGG-
AAGATAGCTGGAGAACTAACCAAA-3P (the underlined sequen-
ces are T7 promoter sequences). PCR products were puri¢ed on 8%
native polyacrylamide gel electrophoresis (PAGE) gel and then used
as templates for in vitro transcription, which was performed with the
RiboMAX1 RNA production system (Promega) from the T7 pro-
moter sequence in the 5P end of the double-stranded DNA template.
The RNA products were puri¢ed on 7 M urea 8% denaturing PAGE
gel and then used for ¢brinogen clotting assay.
2.2. Fibrinogen clotting assay
The e¡ects of three truncated RNA aptamers on clotting were as-
sessed by measuring the time required for clotting with a ¢brometer as
described previously [5]. Truncated RNAs or T705 RNA (100 nM
each) and thrombin (0.2NIH) were pre-incubated before being added
to the ¢brinogen mixture. Bovine ¢brinogen (Sigma) at a concentra-
tion of 2 mg/ml in binding bu¡er containing 0.1% polyethylene glycol
and 1 unit of RNasin (Promega) was added to the reaction with a
¢nal volume of 200 Wl.
2.3. Generation of the ssDNA antisense oligonucleotides
The ssDNA antisense oligonucleotides were synthesized and puri-
¢ed by SBS Genetech. The sequences of these oligonucleotides were
5P-TTTG GTT AGT TCT CCA GCT ATC TTC CAA ATA TAG
TGA GTC GTA TTA-3P (cP), 5P-AGT TCT CCA GCT ATC TTC
CAA A-3P (cP-22), 5P-CCA GCT ATC TTC CAAA-3P (cPt) and
5P-TTG GTT AGT TCT-3P (cP-12) respectively. The e¡ects of these
synthesized ssDNA oligonucleotides were tested by ¢brinogen clotting
assay 15 min after adding the oligonucleotides to the aptamer^bovine
thrombin complex mixture.
2.4. Gel shift assays
Gel shift assay was performed as described previously [5]. RNA
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T705 (0.5 pmol) labeled with -K-32P]UTP was incubated for 15 min
with varying concentrations of the synthesized ssDNA antisense oli-
gonucleotides in binding bu¡er before loading on a native 8% poly-
acrylamide gel at 4‡C. The gel was exposed to X-ray ¢lm at 380‡C.
3. Results
3.1. Minimal sequence determinations
The aptamer T705 is a 68 nt RNA molecule with a poten-
tial stem^loop secondary structure analyzed by the RNA
structure 3.71 (Microsoft). The top two loops of T705, loop
1 and loop 2, were considered as the functional structures of
T705. Three truncated RNA molecules were designed accord-
ing to the secondary structure of T705. Of these, T705a lacked
loop 2, T705b lacked loop 1, and T705c possessed both loop 1
and loop 2 but lacked most of the stem region of T705 (Fig.
1). The ¢brinogen clotting assay results showed that T705c
had the same inhibitory e¡ect on the conversion of ¢brinogen
to ¢brin and clot formation as T705. But the truncated ap-
tamers T705a and T705b had no signi¢cant e¡ects on clot
formation (Fig. 2).
3.2. The reversed activity of the ssDNA antisense
oligonucleotides
A series of ssDNA antisense oligonucleotides complemen-
tary to the di¡erent portions of aptamer T705c were designed
as shown in Fig. 3a. The results showed that signi¢cant re-
versed clot inhibition activity of T705 was observed after add-
ing ssDNA antisense oligonucleotides cP or cP-22 to the ap-
tamer^bovine thrombin complex mixture for 15 min, while the
oligonucleotides cPt and cP12 had no such e¡ects (Fig. 3b).
The results also showed that the inhibition e¡ect of oligonu-
cleotide cP on the clot formation of T705 was dose-dependent
(Fig. 3c).
3.3. Binding ability of the antidote cP to RNA aptamer T705 in
vitro
Gel shift results showed that the functional antidote of
T705, ssDNA antisense oligonucleotide cP, could bind RNA
T705 in vitro. The increase in the amount of ssDNA/RNA
complex was also dose-dependent (Fig. 4), similar to the in-
hibition e¡ect of oligonucleotide cP on the clot formation of
T705 observed above.
4. Discussion
Speci¢c RNA aptamers against bovine thrombin could be
obtained by SELEX technology [5]. In order to further inves-
tigate the relationship between the secondary structures of
aptamer T705 and its inhibition activity to bovine thrombin,
we designed three truncated RNA aptamers according to the
secondary changes of T705. The proposed secondary struc-
tures showed that they could fold as exactly as what we ex-
pected. We found that removal of the ¢xed £ank sequence of
RNA T705 had no e¡ect on its inhibitory activity. However,
Fig. 1. Proposed secondary structures of aptamer T705 and its trun-
cated forms T705a, T705b, and T705c. The aptamer T705 is a 68 nt
RNA molecule with a potential stem^loop secondary structure ana-
lyzed by the RNA structure 3.71 (Microsoft). The top two loops of
T705, loop 1 and loop 2, were considered as the functional struc-
tures of T705. Three truncated RNA molecules were designed ac-
cording to the secondary structure of the T705. Of these, T705a
lacked loop 2, T705b lacked loop 1, and T705c possessed both loop
1 and loop 2 but lacked most of the stem region of T705.
Fig. 2. E¡ects of aptamer T705 and its truncated forms on ¢brin-
ogen cleavage and clot formation. The same inhibition e¡ect on the
conversion of ¢brinogen to ¢brin and clot formation was observed
with the truncated aptamer T705c as with its parental form T705.
But the truncated aptamers T705a and T705b had no signi¢cant ef-
fects on clot formation.
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lack of any sequences of random region of RNA T705 could
lead to the elimination of its speci¢c binding activity to bovine
thrombin, which might be caused by changes of its secondary
structure. This demonstrates that the precise stem^loop struc-
ture is the basic structure for the aptamer to exert its inhibi-
tory activity.
The ability to rationally design antidotes by altering the
conformation and activity of aptamers is unique to aptamers.
Rusconi and his colleagues have successfully taken comple-
mentary RNA oligonucleotides as antidotes capable of e⁄-
ciently reversing the anticoagulant activity of RNA aptamers
against coagulation factor IXa in the clinic. They recom-
mended a safer regulating therapeutics based upon aptamer^
antidote pairs for drug action [6]. Compared with the RNA
antidotes, the ssDNA antidotes have advantages, such as easy
synthesis and much more stable DNA molecules. We designed
four antisense ssDNA oligonucleotides complementary to dif-
ferent portions of T705c as potential antidotes. The clotting
time assay indicated that oligonucleotides cP and cP22 could
completely reverse the anticoagulant activity of T705 in 15 min
and shorten the clotting time in a dose-dependent manner,
while oligonucleotides cPt and cP12 could not. The reason
might be that the pairing between cPt and T705 or cP12 and
T705 is not strong enough to destroy the secondary structure
of T705. The pairing of at least 22 bases from T705 loops
could contribute substantially to the overall binding free en-
ergy, and alter the secondary structure of the aptamer leading
Fig. 4. Native gel analysis of antidote oligonucleotides binding to
aptamer T705. Lane 1: free [32P]UTP-labeled T705 RNA; lanes
2^5: [32P]UTP-labeled T705 RNA was incubated with oligonucleo-
tide cP in di¡erent molar ratios of 1:4, 2:1, 4:1, 8:1 individually;
lane 6: scrambled control ssDNA oligonucleotides incubated with
[32P]UTP-labeled T705 RNA. RNA aptamer T705 (0.5 pmol)
labeled with [K-32P]UTP was incubated for 15 min with varying
concentrations of the synthesized ssDNA antisense oligonucleotide
cP in binding bu¡er before loading on a native 8% polyacrylamide
gel at 4‡C. The gel was exposed to X-ray ¢lm at 380‡C.
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Fig. 3. Designing of antidote oligonucleotides to aptamer T705
RNA. a: Antidote oligonucleotides were designed according to the
second structure of T705c: cP, which is complementary to the ap-
tamer T705c (¢lled circles); cP22, which is complementary to 22 bases
of the aptamer T705c 5P end (open circles); cPt, which is comple-
mentary to 16 bases of the aptamer T705c 5P end (¢lled triangles);
and cP12, which is complementary to 12 bases of the aptamer T705c
3P end (open triangles). b: Reversal e¡ects of oligonucleotide cP,
cP12 and cP22 (250 pmol) on clot formation of aptamer T705
(18 pmol). c: Dose-dependent inhibition e¡ect of oligonucleotide cP
(5, 10, 28, and 56 pmol) on clot formation of aptamer T705
(18 pmol).
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to T705 changing from an active conformation to an inactive
conformation (Fig. 5). In this paper, we also show for the ¢rst
time that ssDNA antisense oligonucleotides are potential anti-
dotes of RNA aptamers. Our paper shows an e¡ective, rapid
approach to get durable antidotes of RNA aptamers that
would be of important usefulness in basic research and drug
screening.
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Fig. 5. Cartoon depicting the antidote oligonucleotide cP binding to aptamer T705. The antidote oligonucleotide cP could bind to aptamer T705
to form an aptamer^antidote complex and cause the loss of biological activity of aptamer T705.
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